Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

ERS Genomics Ltd.

ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. *

 

Period Start 2014-02-17 established
Products Industry CRISPR gene editing technology
  Industry 2 IP services
Persons Person Rhodes, Eric (ERS Genomics 201606– CEO before Horizon Discovery since 201201 before Sigma-Aldrich + Sangamo Biosciences)
  Person 2 Charpentier, Emmanuelle (Helmholtz 201412 Professor at HZI)
     
Region Region Dublin
  Country Ireland, Republic of
  Street 88 Harcourt Street
  City Dublin 2
    Address record changed: 2019-07-31
     
Basic data Employees n. a.
     
    * Document for �About Section�: Bayer AG. (5/17/16). "Press Release: Bayer and ERS Genomics Announce Licensing Agreement for Genome Editing Patents". Leverkusen & Dublin.
     
   
Record changed: 2019-08-04

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for ERS Genomics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top